RxDoctor Payments Data

Allison Boyett

Nurse Practitioner · Pensacola, FLNPI 1093109357

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 208 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Medtronic$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$321
  • Johnson & Johnson$292
  • Ardelyx, Inc.$146
  • Phathom Pharmaceuticals, Inc.$144
  • plus $744 from 13 others

What the payments were for

  • Travel & lodging$95023%
  • Food & beverage$3,01974%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,080 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$49,407
Medicare patients
387
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide18$23,201
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag22$2,630
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates37$2,373
Lubiprostone16$1,365
Omeprazole107$1,351
Famotidine60$979
Pantoprazole Sodium79$840
Dicyclomine Hcl28$718
Sucralfate34$535
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl33$502
Esomeprazole Magnesium16$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,387$23,20118 claims
Braintree Laboratories, Inc.Suflave$14$2,63022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →